Last reviewed · How we verify
NCT06344416
Open Label, Controlled, Post Marketing, Registry Study of Ribociclib (Ribo) Treatment Adherence and Patient Reported Outcomes in Participants Using ReX Technology Platform
NA trial testing Use of ReX to dispense and monitor solid oral medication therapy. in Any Solid Oral Medication in 200 participants. Currently enrolling.
30 March 2025
Quick facts
| Lead sponsor | Dosentrx Ltd. |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | single |
| Primary purpose | supportive care |
| Enrollment | 200 |
| Start date | 30 March 2024 |
| Primary completion | 30 March 2025 |
| Estimated completion | 30 January 2026 |
| Sites | 4 locations across United States |
Drugs / interventions tested
- Use of ReX to dispense and monitor solid oral medication therapy.
Conditions studied
- Any Solid Oral Medication — all drugs for Any Solid Oral Medication →
Sponsor
Dosentrx Ltd.
Who can join
18 and older, any sex, with Any Solid Oral Medication. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Primary Objective: • To assess the persistence of ReX technology platform use, measured by the percentage (%) of participants who used ReX: 1) throughout the study period and 2) before the treatment discontinuation. Secondary Objective: • To evaluate the impact of the ReX technology platform on ribo treatment duration and ribo dose taking adherence as compared to control group.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06344416
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Use of ReX to dispense and monitor solid oral medication therapy.
Trials testing the same drug.
- NCT06335758 — Non-randomized Observational Study to Evaluate ReX® in the Management of Solid Oral Medication. · unknown
Other Dosentrx Ltd. trials
Trials by the same sponsor.
- NCT06335758 — Non-randomized Observational Study to Evaluate ReX® in the Management of Solid Oral Medication. · unknown
- NCT04215796 — Evaluation of the ReX-C System, in Patients Receiving CFTR Modulators for the Treatment of Cystic Fibrosis (CF). · NA · unknown
- NCT03424330 — Evaluation of ReX-C System in Measurement and Improvement of Patients' Adherence. · NA · unknown
- NCT03134001 — Evaluation of Oral PCA Device - PCoA™ Acute · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06344416 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dosentrx Ltd.
- Last refreshed: 12 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06344416.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing